Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H ( (HK:2591) ) has provided an announcement.
Guangzhou Innogen Pharmaceutical Group Co., Ltd. has announced the completion of the first patient dosing in its Phase II clinical trial for Efsubaglutide Alfa, a core product aimed at treating obesity and being overweight, in Australia. This development marks a significant step in the company’s efforts to expand its market presence in the obesity treatment sector, although the company cautions that there is no guarantee of successful development or marketing of the product.
More about Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
Guangzhou Innogen Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in China, focusing on the development of innovative treatments. The company is engaged in the pharmaceutical industry, with a primary focus on developing medications for conditions such as obesity and being overweight.
Average Trading Volume: 3,356,821
For a thorough assessment of 2591 stock, go to TipRanks’ Stock Analysis page.